Tc-99m-galactosyl-neoglycoalbumin: in vivo characterization of receptor-mediated binding to hepatocytes.
The biodistribution and kinetics of a receptor-binding hepatic radiopharmaceutical, Tc-99m-galactosyl-neoglycoalbumin (Tc-NGA), were investigated using mammalian and avian models. The radiopharmaceutical exhibited four significant features associated with receptor-mediated binding at the hepatocyte membrane in mammals: (a) high tissue specificity, (b) high molecular specificity, (c) affinity-dependent uptake, and (d) dose-dependent uptake. Diminished hepatic uptake by the avian model illustrated low nonspecific binding. The kinetic sensitivity to ligand-receptor affinity and stoichiometry illustrated the principal feature of receptor-binding radio-pharmaceuticals, namely, quantitative assessment of tissue function based upon the biochemical interaction of a ligand and its specific receptor.
D000418:Albumins / Q000008:administration & dosage / Q000378:metabolism*; D000818:Animals; D037263:Asialoglycoprotein Receptor; D002352:Carrier Proteins / Q000378:metabolism; D002462:Cell Membrane / Q000378:metabolism; D002645:Chickens; D004305:Dose-Response Relationship, Drug; D007700:Kinetics; D008099:Liver / Q000000981:diagnostic imaging / Q000378:metabolism*; D015609:Organotechnetium Compounds; D011817:Rabbits; D011877:Radionuclide Imaging; D011955:Receptors, Drug / Q000378:metabolism*; D013667:Technetium / Q000008:administration & dosage / Q000378:metabolism*; D014018:Tissue Distribution
D000418:Albumins; D037263:Asialoglycoprotein Receptor; D002352:Carrier Proteins; D015609:Organotechnetium Compounds; D011955:Receptors, Drug; C027122:hepatic sialoglycoprotein receptor; C036586:technetium Tc 99m neogalactoalbumin; D013667:Technetium